Role of Circulating suPAR in FSGS Focal Segmental Glomerulosclerosis (FSGS) is a severe glomerular disease that is characterized by podocyte injury, proteinuria and progressive renal decline, the disease is likely to recur after transplantation in 30% of adults and even in higher number in children. Recently, soluble urokinase plasminogen activator receptor (suPAR) has been found to be elevated in the serum of the majority of patients with FSGS. Animal experiments suggested that suPAR caused podocyte injury and FSGS-type changes in rodents through activation of podocyte beta 3 integrin. As suPAR levels are increased due to variables, such as cancer or infection; and do not routinely present with proteinuria, this proposal seeks to define the precise form (s) of suPAR that is/are acting as a causative factor for focal segmental glomerulosclerosis (FSGS). We hypothesize that diverse effects of suPAR in different diseases are due to different forms of suPAR. Under this grant application we test hypothesis that only the specific form(s) of suPAR, i.e. hypoglycosylated form(s), is (are) responsible for FSGS.
Aim 1 will identify pathological form(s) of suPAR in FSGS patients.
Aim 2 will test pathological suPAR in mice.
Aim 3 will be aimed to develop a more specific ELISA test and Aim 4 will assess the risk of a common genetic variant (P1A2) in the beta 3 gene that might allow integrin hyperactivation in podocytes. In sum, this research program will potentially unravel a major cause of FSGS and might lead to a refined treatment for patients with the disease.
The goal of this grant proposal is to understand the pathogenesis of Focal and Segmental Glomerulosclerosis (FSGS). If our hypothesis is correct, the identification of kidney-pathogenic forms of the soluble urokinase plasminogen activator receptor suPAR will allow for improved risk stratification of patients affected with the disease. I will also allow for novel therapies that treat a root cause of native and post-transplant FSGS and reduce the burden of renal disease for our fellow humans.
|Luo, Shengyuan; Coresh, Josef; Tin, Adrienne et al. (2018) Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clin J Am Soc Nephrol 13:1013-1021|
|Sever, Sanja; Schiffer, Mario (2018) Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases. Kidney Int 93:1298-1307|
|Alasfar, Sami; Matar, Dany; Montgomery, Robert A et al. (2018) Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation. Transplantation 102:e115-e120|
|Hayek, Salim S; Ko, Yi-An; Awad, Mosaab et al. (2017) Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. Kidney Int Rep 2:425-432|
|Dande, Ranadheer R; Peev, Vasil; Altintas, Mehmet M et al. (2017) Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. J Diabetes Res 2017:3232848|
|Drechsler, Christiane; Hayek, Salim S; Wei, Changli et al. (2017) Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis. Clin J Am Soc Nephrol 12:1265-1273|
|Hayek, Salim S; Koh, Kwi Hye; Grams, Morgan E et al. (2017) A tripartite complex of suPAR, APOL1 risk variants and ?v?3 integrin on podocytes mediates chronic kidney disease. Nat Med 23:945-953|
|Schaefer, Franz; Trachtman, Howard; Wühl, Elke et al. (2017) Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatr 171:e172914|
|Hahm, Eunsil; Wei, Changli; Fernandez, Isabel et al. (2017) Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med 23:100-106|
|Hayek, Salim S; Sever, Sanja; Ko, Yi-An et al. (2015) Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med 373:1916-25|
Showing the most recent 10 out of 28 publications